

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. KRAS mutations are present in approximately what proportion of patients with pancreatic cancer?**
  - 15%
  - 30%
  - 60%
  - 90%
- 2. The ongoing Phase III SWOG-S2001 study is evaluating olaparib in combination with which of the following agents for patients with metastatic pancreatic ductal adenocarcinoma and a BRCA1/2 mutation?**
  - Atezolizumab
  - Durvalumab
  - Nivolumab
  - Pembrolizumab
- 3. What is the target of the novel agent zolbetuximab?**
  - CD38
  - CLDN18.2
  - FGFR
  - HER2
- 4. The Phase III NAPOLI-3 trial evaluating liposomal irinotecan/oxaliplatin/5-fluorouracil/leucovorin (NALIRIFOX) versus *nab* paclitaxel/gemcitabine for previously untreated metastatic pancreatic adenocarcinoma (PAD) demonstrated clinically meaningful and statistically significant improvement with NALIRIFOX in which of the following endpoints?**
  - Progression-free survival
  - Overall survival
  - Both a and b
  - Neither a nor b
- 5. The ongoing Phase III PANOVA-3 study is evaluating tumor treating fields with gemcitabine and *nab* paclitaxel in which of the following settings?**
  - First-line therapy for locally advanced PAD
  - First-line therapy for metastatic PAD
  - Second-line therapy for locally advanced PAD
  - Second-line therapy for metastatic PAD
  - Late-line therapy for locally advanced PAD
  - Late-line therapy for metastatic PAD